BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Novartis' Japan arm failed to report 2,500 cases of serious side effects
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Novartis' Japan arm failed to report 2,500 cases of serious side effects
Sep. 10, 2014
By
Catherine Makino
No Comments
TOKYO – The Japanese arm of Swiss pharma giant Novartis AG admitted to government regulators it failed to report more than 2,500 cases of serious side effects in patients who had received its leukemia and cancer drugs.
BioWorld